| Dear Fellow Trader, |
| I hope this trading day has been good to you! I am sending you trade ideas for tomorrow. So you can have enough time to take action on our trades ideas. |
Phase 2 Trials Incoming - Could NNVC Be the Next Biotech Giant? (ad)*
Wall Street is taking notice of NanoViricides (NYSE: NNVC) as its lead drug NV-387 prepares for Phase 2 trials targeting MPox and broader viral threats. Zacks just issued a $7 valuation, highlighting NV-387’s unique ability to neutralize viruses before infection—and its potential use across measles, RSV, influenza, and coronaviruses. With biodefense implications, possible BARDA funding, and a path toward government stockpiles, NNVC offers asymmetric upside ahead of key clinical milestones.
See why this antiviral story is gaining momentum now. |
| Options Trade Ideas (Volatility Rush Strategy) |
| The basic option trade idea is to buy an at-the-money straddle while the options premium is cheap. |
| In assessing this trade, you need to do your homework to ensure you are not paying too much for the straddle. |
| As the earnings date approaches, the implied volatility (IV) should increase, resulting in greater price movement. |
| However, be aware that you should close your position before the announcement comes out in order to maximize your profit potential. That's because once earnings are released, IV will fall dramatically, which will greatly reduce your opportunity to profit on the trade. |
| The stocks (with Weekly Options) below are announcing earnings in next few weeks. Our proprietary volatility algorithm suggests these stocks are likely to experience high volatility as earnings day approaches. |
| |
|
 | Before Market Open |  | After Market Close | |
| *Predicted Volatility % based on our Proprietary Volatility Predication Model. We are expecting that stock price will likely to reach % in either direction by the end of next trading session after Earnings are released and not necessarily the closing volatility %. |
With a $7 Valuation, NNVC Could Shake Up the Biotech Space in 2026 (ad)*
This emerging biotech company is advancing a broad-spectrum antiviral into Phase 2 trials, with potential applications in public health and biodefense. New research highlights upcoming catalysts that could significantly impact its future trajectory.
Learn why NNVC is on the verge of redefining the antiviral market |
Major Trial Phase Puts This Biotech Center Stage (ad)*
A little-known biotech is quietly preparing what could be one of the most important antiviral breakthroughs of the decade. NanoViricides (NYSE: NNVC) is advancing NV-387 — a broad-spectrum antiviral designed to neutralize viruses before they infect cells. With Phase 2 trials targeting MPox, measles, and respiratory viruses ahead — and Zacks issuing a $7 valuation — this small-cap story is starting to turn heads on Wall Street. Few investors are paying attention… yet.
π See Why Analysts Are Watching This Antiviral Breakout Now |
| At StockEarnings, we're really excited to help you trade more confidently. To that end, we're constantly developing new content to go alongside our platform insights, which will further our mission to help you become a better trader. |
| To your trading success, |
| Hiral Ghelani |
| Founder & CEO |
| StockEarnings, Inc |
| 33 SE 4th St, Suite 100, Boca Raton, FL 33432 USA |
| W: 877.6.STOCKS (Mon to Sat | 9am to 5pm EST | Feel Free to Call Us) |
| π Beat Volatility with These Dividend Powerhouses | | After the recent market volatility, income picks are in hot demand. Our free report teases High-Yield Dividend Stocks that could anchor your returns: | | π₯ [Download Your Free Guide Now] . | |
|
| (ad)* This message is a PAID ADVERTISEMENT for NanoViricides, Inc (NYSE:NNVC) from Interactive Offers. StockEarnings, Inc. has received a fixed fee of $8000 from Interactive Offers for multiple Dedicated Email Sends, Newsletter Sponsorships and SMS Sends between Dec 19, 2025 and Dec 25, 2025. Other than the compensation received for this advertisement sent to subscribers, StockEarnings and its principals are not affiliated with either NanoViricides, Inc (NYSE:NNVC) or Interactive Offers. StockEarnings and its principals do not own any of the stocks mentioned in this email or in the article that this email links to. Neither StockEarnings nor its principals are FINRA-registered broker-dealers or investment advisers. The content of this email should not be taken as advice, an endorsement, or a recommendation from StockEarnings to buy or sell any security. StockEarnings has not evaluated the accuracy of any claims made in this advertisement. StockEarnings recommends that investors do their own independent research and consult with a qualified investment professional before buying or selling any security. Investing is inherently risky. Past-performance is not indicative of future results. Please see the disclaimer regarding NanoViricides, Inc (NYSE:NNVC) on EQUISCREEN website for additional information about the relationship between Interactive Offers and NanoViricides, Inc (NYSE:NNVC).
StockEarnings, Inc (SE) is a research service not owned or managed by registered brokers and therefore this site does not make any investment recommendations. The information provided in this newsletter is not guaranteed as to the accuracy or completeness. Each user of SE chooses to do trades at their sole discretion and risk. SE is not responsible for gains/losses that may result in the trading of these securities. This newsletter includes paid advertisements. The source of all third-party content in which SE receives some sort of compensation, is clearly and prominently identified herein as "ad" or "Sponsored". Although we have sent you these advertisements, SE does not specifically endorse any third-party product nor is it responsible for the content of the advertisement or the experience with the third-party advertiser. Furthermore, we make no guarantee or warranty about what is advertised. All investments involve risk, losses may exceed the principal invested, and the past performance of a security, industry, sector, market, or financial product does not guarantee future results or returns. Please click here for SE Disclaimers. StockEarnings Inc 33 SE 4th St, Suite 100, Boca Raton, FL 33432 USA | W: 877.6.STOCKS |
Unsubscribe
Today's Bonus Content: π° The $13 Trillion Market You'll Never See on CNBC
|
0 Response to "π Your Premium Trade Alerts (Dec 19)"
Post a Comment